Frontlight ResearchEarly access
WithdrawnNo phase
Diabetic Cardiomyopathy and Heart Failure
Key facts
- Who runs it
- University of Louisville
- Where
- Louisville, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- Jul 2025
- Ended
- Jun 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Probiotic
- Record updated
- 31 January 2025
- Why it stopped
- Did not receive funding as anticipated.
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- -Diabetic subjects with high blood glucose levels
Who cannot take part
- Comorbidities affecting glucose levels and cardiac function
Where in United States
- University of Louisville School of MedicineLouisville, United States
About the trial
What the trial wants to find out
This study will demonstrate the beneficial effects of ketone bodies in type 1 diabetes (T1D) patients and will have significant translational applications to prevent serious metabolic conditions such as T1D induced diabetic cardiomyopathy (DCM).
The 2 groups in the trial
- Control subjects (non-diabetic).Other group
Control subjects (non-diabetic): 10 subjects: No intervention (placebo). 10 subjects: Intervention (probiotic)
Treatment: Probiotic
- Diabetic SubjectsOther group
Diabetic subjects: 10 subjects: No intervention (placebo). 10 subjects: Intervention (probiotic)
Treatment: Probiotic
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Preventing Diabetic Cardiomyopathy and Heart Failure by Ketone Bodies
- Record updated
- 31 January 2025